Related Experiment Video
Updated: May 5, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Experimental autoimmune encephalomyelitis repressed by microglial paralysis
Frank L Heppner1, Melanie Greter, Denis Marino
1Institute of Neuropathology, University Hospital Zurich, CH-8091 Zurich, Switzerland.
Abstract:
Although microglial activation occurs in inflammatory, degenerative and neoplastic central nervous system (CNS) disorders, its role in pathogenesis is unclear. We studied this question by generating CD11b-HSVTK transgenic mice, which express herpes simplex thymidine kinase in macrophages and microglia. Ganciclovir treatment of organotypic brain slice cultures derived from CD11b-HSVTK mice abolished microglial release of nitrite, proinflammatory cytokines and chemokines. Systemic ganciclovir administration to CD11b-HSVTK mice elicited hematopoietic toxicity, which was prevented by transfer of wild-type bone marrow. In bone marrow chimeras, ganciclovir blocked microglial activation in the facial nucleus upon axotomy and repressed the development of experimental autoimmune encephalomyelitis. We conclude that microglial paralysis inhibits the development and maintenance of inflammatory CNS lesions. The microglial compartment thus provides a potential therapeutic target in inflammatory CNS disorders. These results validate CD11b-HSVTK mice as a tool to study the impact of microglial activation on CNS diseases in vivo.
Insights
Targeting microglia, the immune cells of the central nervous system (CNS), can halt inflammatory CNS diseases. This study validates CD11b-HSVTK mice as a tool to explore microglial roles in CNS disorders.
Area of Science:
- Neuroimmunology
- Central Nervous System (CNS) Disorders
- Cellular Biology
Background:
- Microglial activation is observed in various CNS disorders, but its precise role in disease pathogenesis remains unclear.
- Understanding microglial function is crucial for developing targeted therapies for inflammatory CNS conditions.
Purpose of the Study:
- To investigate the role of microglial activation in the pathogenesis of inflammatory central nervous system (CNS) disorders.
- To validate CD11b-HSVTK transgenic mice as a model for studying microglial function in CNS diseases.
Main Methods:
- Generation of CD11b-HSVTK transgenic mice expressing herpes simplex thymidine kinase in macrophages and microglia.
- Treatment with ganciclovir to selectively eliminate or inhibit microglia.
- Analysis of microglial activation markers and inflammatory responses in brain slice cultures and in vivo models (axotomy, experimental autoimmune encephalomyelitis).
- Bone marrow chimera experiments to assess hematopoietic toxicity and microglial-specific effects.
Main Results:
- Ganciclovir treatment abolished microglial release of inflammatory mediators (nitrite, cytokines, chemokines) in vitro.
- Systemic ganciclovir administration in CD11b-HSVTK mice led to hematopoietic toxicity, preventable by wild-type bone marrow transfer.
- Ganciclovir administration in bone marrow chimeras blocked microglial activation post-axotomy and repressed experimental autoimmune encephalomyelitis development.
- Microglial paralysis effectively inhibited the development and maintenance of inflammatory CNS lesions.
Conclusions:
- Microglial activation plays a significant role in the development and progression of inflammatory CNS disorders.
- Targeting the microglial compartment offers a potential therapeutic strategy for inflammatory CNS diseases.
- CD11b-HSVTK mice serve as a valuable tool for in vivo studies on the impact of microglial activation in CNS pathology.
More Related Videos
Related Concept Videos
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Myasthenia Gravis ll: Pathophysiology

